BiotechTube
Glycan Therapeutics

Glycan Therapeutics

Cambridge, United States· Est.
glycantherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $4.5M

Overview

Glycan Therapeutics is a private, pre-clinical stage biotech pioneering a new class of medicines based on glycobiology. The company's core technology platform enables the rational design of glycan-targeting molecules, including antibodies and vaccines, to modulate immune responses and disrupt disease mechanisms. Its initial pipeline focuses on oncology and infectious diseases, seeking to address limitations of current therapies. As a platform company, it operates a pre-revenue business model typical of early-stage biotechs, relying on venture funding and potential partnerships for advancement.

OncologyInfectious Disease

Technology Platform

Proprietary platform for the discovery and engineering of glycan-targeting therapeutics and vaccines, combining computational modeling, glycan array screening, and protein engineering to develop high-affinity binders against disease-specific carbohydrate targets.

Funding History

2
Total raised:$4.5M
Seed$4M
Grant$500K

Opportunities

The field of glyco-immunology represents a vast, underexplored frontier for drug discovery with potential for first-in-class therapies.
The platform's applicability across both oncology and infectious diseases allows for pipeline diversification and multiple value inflection points.
Growing interest in novel vaccine modalities and targeted immunotherapies creates a favorable environment for partnership and investment.

Risk Factors

High scientific risk associated with clinically validating a novel and complex biological target class.
As a pre-clinical, private company, it faces significant funding and execution risk on the path to the clinic.
Competition from other entities exploring glycobiology and from established modalities in its target indications is a persistent threat.

Competitive Landscape

The competitive landscape is emerging but fragmented, including a handful of private biotechs (e.g., Palleon Pharmaceuticals, Asphelia Therapeutics) and significant academic research consortia focused on glycotherapeutics. Large pharma companies are generally observers or collaborators at this early stage. Differentiation will depend on the robustness of the platform and the clinical success of first-generation candidates.

More companies in Biologics / Biosimilars →More companies in United States →